Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03695250 · ClinicalTrials.gov registry record · Phase 1
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
A Phase 1 study, sponsored by Edward Kim.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03695250: Clinical Trial Phase 1 study, sponsored by Edward Kim.
NCT03695250 is a Phase 1 study that was terminated before completion, run by Edward Kim. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03695250, a Phase 1 study, was terminated before completion, sponsored by Edward Kim.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of IDO1 inhibitor BMS-986205 (BMS-986205) when given together with nivolumab and how well it works as first or second line therapy in treating patients with liver cancer. BMS-986205 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving BMS-986205 and nivolumab may work better in treating patients with liver cancer.
Primary Outcome
Number of participants with adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0
Interventions
- BIOLOGICAL Nivolumab
- DRUG IDO1 Inhibitor BMS-986205
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-10-16 |
| Est. Completion | 2021-03-12 |
| Phase | Phase 1 |
Why NCT03695250 stopped before completion
NCT03695250 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03695250 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03695250 about?
NCT03695250 is a clinical study titled "BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer". This phase I/II trial studies the side effects and best dose of IDO1 inhibitor BMS-986205 (BMS-986205) when given together with nivolumab and how well it works as first or second line therapy in treating patients with liver cancer. BMS-986205 may stop the growth of tumor cells by blocking some of th...
What is the current status of trial NCT03695250?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2018-10-16. Estimated completion is 2021-03-12.
What interventions are being tested in trial NCT03695250?
The interventions under investigation include: Nivolumab (BIOLOGICAL), IDO1 Inhibitor BMS-986205 (DRUG).
Who is sponsoring clinical trial NCT03695250?
This trial is sponsored by Edward Kim, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03695250's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI